Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Represents Merck in $1.85B Acquisition of Pandion Therapeutics

February 25, 2021

WASHINGTONCovington represented Merck & Co., Inc. in its definitive agreement  under which Merck, through a subsidiary, will acquire Pandion Therapeutics, Inc., at a price of $60.00 per share in cash, representing an approximate total equity value of $1.85 billion.

Pandion is a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases.

The Covington team included Catherine Dargan and Michael Riella (corporate), Erika Skougard (employee benefits), and Van Ellis (life sciences transactions).

Share this article: